Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schoffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Sci Transl Med 9:eaao1690 (2017)
DOI:10.1126/scitranslmed.aao1690

Avapritinib Approved for GIST Subgroup.

Cancer Discov 2159-8290.CD-NB2020-003 (2020)
DOI:10.1158/2159-8290.CD-NB2020-003

Florou V, Trent JC, Wilky BA

Precision medicine in gastrointestinal stromal tumors.

Discov Med 28:267-276 (2019)

Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schoffski P

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.

Clin Cancer Res 25:609-618 (2019)
DOI:10.1158/1078-0432.CCR-18-1858